Aliskiren Hemifumarate/Valsartan

半延胡索酸阿利吉仑/缬沙坦

Report date: 2026/01/21 14:10:51

Base Information

Drug NameAliskiren Hemifumarate/Valsartan
Drug Alias NameAliskiren fumarate and Valsartan缬沙坦/半延胡索酸阿利吉仑阿利吉仑+缬沙坦Aliskiren Hemifumarate and ValsartanAliskiren Fumarate/Valsartan +[7] 
ClassificationSmall molecules
Mechanisms of ActionRenin inhibitorsAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1Renin
Therapy Area/IndicationsAcutely decompensated congestive heart failureOverweightObesity, Abdominal +[12] 
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2009/09/16
Country/TerritoryCzechiaBelgiumCanada +[53] 
CombinationsYes ValsartanAliskiren Hemifumarate
Global Highest StatusWithdrawn
Highest Status in ChinaPending
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Medical Center GroningenNovartis Pharma AgUniversity Of Michigan
Active IndicationsN/A
Inactive IndicationsAcutely decompensated congestive heart failureOverweightObesity, Abdominal +[12] 

Other Information

ATC CodeC09DX02
Related LinksKEGG